Social support and clinical outcomes during antiviral therapy for chronic hepatitis C

Journal of Psychosomatic Research

Volumn 71, Issue 5, 2011, Pages 349-356

  Evon, Donna M ^a   Esserman, Denise A ^a,b   Ramcharran, Darmendra ^c,d   Bonner, Jason E ^a   Fried, Michael W ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c NONE

^d PFIZER INC   (United States)

Author keywords

Depression; Efficacy; Interferon; Social support; Treatment; Virological response

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; DEPRESSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HUMAN; IRRITABILITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL OUTCOME STUDY SOCIAL SUPPORT SURVEY; MENTAL DISEASE; NEUROTOXICITY; PAIN; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SOCIAL SUPPORT; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; SOCIAL SUPPORT; TREATMENT OUTCOME;

EID: 80053963174     PISSN: 00223999     EISSN: 18791360     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2011.05.003     Document Type: Article

References (45)

1. Seeff LB, Hoofnagle JH National Institutes of Health consensus development conference: management of hepatitis C: 2002. Hepatology 2002, 36(5 Suppl. 1):S1-S2.
2. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341(8):556-562.
3. Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003, 98(9):2060-2063.
4. Kim WR The burden of hepatitis C in the United States. Hepatology 2002, 36(5 Suppl. 1):S30-S34.
5. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000, 31(3):777-782.
6. Di Bisceglie AM, Hoofnagle JH Optimal therapy of hepatitis C. Hepatology 2002, 36(5 Suppl. 1):S121-S127.
7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13):975-982.
8. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005, 41(4):790-800.
9. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343(23):1666-1672.
10. Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, et al. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol 2008, 6(2):234-241.
11. Janke EA, McGraw S, Garcia-Tsao G, Fraenkel L Psychosocial issues in hepatitis C: a qualitative analysis. Psychosomatics 2008, 49(6):494-501.
12. Zickmund S, Ho EY, Masuda M, Ippolito L, LaBrecque DR 'They treated me like a leper': stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med 2003, 18(10):835-844.
13. McHutchison JG, Poynard T Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999, 19(Suppl. 1):57-65.
14. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003, 64(6):708-714.
15. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339(21):1485-1492.
16. Golden J, O'Dwyer AM, Conroy RM Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 2005, 27(6):431-438.
17. Loftis JM, Matthews AM, Hauser P Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs 2006, 66(2):155-174.
18. Cormier M The role of hepatitis C support groups. Gastroenterol Nurs 2005, 28(3 Suppl.):S4-S9.
19. Burgoyne RW Exploring direction of causation between social support and clinical outcome for HIV-positive adults in the context of highly active antiretroviral therapy. AIDS Care 2005, 17(1):111-124.
20. Rifai MA, Indest D, Loftis J, Hauser P Psychiatric management of the hepatitis C patient. Curr Treat Options Gastroenterol 2006, 9(6):508-519.
21. Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G Patients' experiences related to anti-viral treatment for hepatitis C. Patient Educ Couns 2006, 62(1):148-155.
22. Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010, 22(3):270-277.
23. Groessl EJ, Weingart KR, Kaplan RM, Clark JA, Gifford AL, Ho SB Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans. J Gen Intern Med 2008, 23(12):1959-1965.
24. Evon DM, Ramcharran D, Belle SH, Terrault NA, Fontana RJ, Fried MW Virahep-C study group. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the VIRAHEP-C Study. Am J Gastroenterol 2009, 104:2949-2958.
25. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131(2):470-477.
26. Sherbourne CD, Stewart AL The MOS social support survey. Soc Sci Med 1991, 32(6):705-714.
27. Radloff LS The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977, 1(3):385-401.
28. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000, 12(3):255-266.
29. Cohen J A power primer. Psychol Bull 1992, 112(1):155-159.
30. Zou G A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004, 159(7):702-706.
31. Cohen S Syme SLEd. Social support and health 1985, Academic Press, San Diego, CA US.
32. Ganster DC, Victor B The impact of social support on mental and physical health. Br J Med Psychol 1988, 61(Pt 1):17-36.
33. Reblin M, Uchino BN Social and emotional support and its implication for health. Curr Opin Psychiatry 2008, 21(2):201-205.
34. McHutchison JG, Bacon BR, Owens GS Making it happen: managed care considerations in vanquishing hepatitis C. Am J Manag Care 2007, 13(Suppl. 12):S327-S336.
35. Fried MW Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36(5 Suppl. 1):S237-S244.
36. Cohen S, Wills TA Stress, social support, and the buffering hypothesis. Psychol Bull 1985, 98(2):310-357.
37. Bozo O, Toksabay NE, Kurum O Activities of daily living, depression, and social support among elderly Turkish people. J Psychol 2009, 143(2):193-205.
38. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010, 138(1):123-135.
39. Darke S, Hall W, Wodak A, Heather N, Ward J Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict 1992, 87(5):733-742.
40. Zacks S, Beavers K, Theodore D, Dougherty K, Batey B, Shumaker J, et al. Social stigmatization and hepatitis C virus infection. J Clin Gastroenterol 2006, 40(3):220-224.
41. Willenbring ML Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches. AIDS 2005, 19(Suppl. 3):S227-S237.
42. O'Brien AP, Cross WM, Higgs P, Munro I, Bloomer MJ, Chou KR Australians living with and managing hepatitis C. Issues Ment Health Nurs 2010, 31(8):520-524.
43. Pherson-Baker S, Jones D, Duran RE, Klimas N, Schneiderman N Development and implementation of a medication adherence training instrument for persons living with HIV: the MATI. Behav Modif 2005, 29(2):286-317.
44. Martin-Santos R, ez-Quevedo C, Castellvi P, Navines R, Mique lM, Masnou H, et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther 2008, 27(3):257-265.
45. Lang JP, Melin P, Ouzan D, Rotily M, Fontanges T, Marcellin P, et al. Pegylated interferon-alpha2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study. Antivir Ther 2010, 15(4):599-606.